Supplementary Figure 1. Species origin of transplantable PDX lines.

A. Expression of human AFP, ALB, EPCAM, and GAPDH in PDX lines. Most of the PDX lines express human genes except HS125TG1.

B. Expression of human AFP, ALB, EPCAM, and GAPDH in PDX lines. HS125TG1 expresses mouse genes.

Supplementary Figure 2. PDXs maintain the features of parental tumor histology.

A. H&E staining of parental tumors, passaged PDX lines, and thawed PDXs. Scale bar = 100µm.

B. IHC staining of parental tumor samples and PDXs with anti-Hep Par1, anti-EpCAM, and anti-CK19 antibodies. Scale bar = 100µm.

C. H&E staining of PDXs generated from biopsies and corresponding thawed PDXs. Scale bar = 100µm.

D. IHC staining of PDXs generated from biopsies with anti-Hep Par1, anti-EpCAM, and anti-CK19 antibodies. Scale bar = 100µm.

Supplementary Figure 3. Growth of established PDX lines in different recipient models.


A. Growth curve of CCA-HS131 PDX in NSG mice, NSG mice after PHx, and FRG mice with NTBC water cycling (n = 6, 6, 6).


B. Growth curve of CCA-HB163 PDX in NSG mice, NSG mice after PHx, and FRG mice with NTBC water cycling (n = 6, 6, 4).


C. Pictures of CCA-HS131 PDX in the livers of NSG mice, NSG mice after PHx, and FRG mice with NTBC water cycling. Scale bar = 5 cm.

Supplementary Table 1. Clinical data and PDX engraftment of all samples.

Supplementary Table 2. Engraftment rate analysis of tumors of different grade and source (resection or biopsy; HCC or CCA). *, p=0.02 compared to moderately differentiated HCC surgical samples (Fisher's exact t test).







5cm

Name D D Nam Percentage of the control of the con | March | Marc | March | Marc 041 1 201 1 48 127 49 123 147 147 147 148 32 466 74 66 64 123 179 59 59 41 17 29 59 41 17 17 18 | Company | Comp 26 - 100 - 1 12/7/2016 5/7/2018 8/7/50145 1/100% 9/202015 6/14/2016 9/12/2015 9/12/2015 3/22/2018 4/6/0047 4/6/2016 7/18/2017 11/12/2017 4/4/2016 7/28/2016 17 G Gran 46.5 Year 25.4 No 34.7 No 30.1 No 30.1 No 30.6 15.5 Ver 18.1 No 9132017 1/112017 1/21/2018 2614 Yes
7 Yes
10 20 Ves
8 Government remail
10 14 Ves
14 Yes Ismohom 110 140 110 441 145 146 148 118 160 114 120 64 466 466 467 160 22 160 207 144 144 122 144 65 23 134 182 46.09 09 111 12 11 09 40 41 40 41 11 12 13 13 6/77/0047 40/45/0047 12/52017 3 18 76 6 94 95 97 91 15 94 15 26 4 127 69 42 45 33 40 44 46 44 30 31 37 31 42 32 44 73 40 907 34 433 47 66 84 9 67 89 21 171 29 57 36 975 96 98 98 98 98 91 111 211 215 146 29 483 42 99 66 64 76 64 66 60 60 70 211 260 62 293 58 06 05 05 00 10 00 00 01 02 28 03 42 06 1 2 2 1 2 2 1 1 0 0 0 0 0 23 463 56 40 24 25 95 22 122 65 52 5 5 5 6 5 24 42 25 42 29 28 28 26 27 42 28 24 42 42 44 44 44 27 45 65 65 70 145 71 281 28 62 41 45 60 917 60 45 60 917 60 45 60 917 60 46 129 014 88 109 211 129 211 155 223 96 103 485 195 045 445 07 09 12 08 08 13 12 07 07 05 16 11 06 02 07 07 08 150 129 244 150 000 68 164 220 42 167 125 204 016 47 125 201 016 47 125 200 016 016 017 1 0 2 1 4 3 1 1 0 0 0 4 9 a 7 a 11 9 7 10 11 6 7 8212017 11/162017 01/10018

Supplementary Table 2. Engraftment rate analysis of tumors of different grade and source (resection or biopsy; HCC or CCA). *, p=0.02 compared to moderately differentiated HCC surgical samples (Fisher's exact t test).

| | | | HCC-PDXs | | Engraftment time | Passageable | Passageable |
|------------------|------------------|-----------|----------|------------|------------------|-------------|-------------|
| Туре | Grade | Implanted | Amount | Percentage | Weeks | HCC-PDX | Line ID |
| HCC Resection | N/A | 3 | 0 | 0.0% | 1 | 1 | / |
| | well | 1 | 1 | 100.0% | 29.4 | \ | \ |
| | well to moderate | 1 | 1 | 100.0% | 19.7 | 1 | HCC-HS141 |
| | moderate | 43 | 9 | 20.9% | 27.5 | \ | \ |
| | moderate to poor | 4 | 1 | 25.0% | 19.4 | 1 | HCC-HS157 |
| | | | | | | | HCC-HS84 |
| | poor | 17 | 5 | 29.4% | 23.9 | 3* | HCC-HS119 |
| | | | | | | | HCC-HS125 |
| | Total | 69 | 17 | 24.6% | 25.4 | 5 | |
| | | | | | | | |
| | | | HCC-PDXs | | Engraftment time | Passageable | Passageable |
| Type | Grade | Implanted | Amount | Percentage | Weeks | HCC-PDX | Line ID |
| HCC Biopsy | N/A | 9 | 1 | 11.1% | 38.6 | 0 | 1 |
| | well | 1 | 0 | 0.0% | \ | \ | \ |
| | moderate | 11 | 2 | 18.2% | 21.6 | 1 | HCC-HB179 |
| | moderave to poor | 1 | 0 | 0.0% | \ | \ | \ |
| | poor | 2 | 0 | 0.0% | 1 | \ | \ |
| | total | 24 | 3 | 12.5% | 27.3 | 1 | |

| | | | CCA-PDXs | | Engraftment time | Passageable | Passageable |
|------------------|------------------|-----------|----------|------------|------------------|-------------|-------------|
| Type | Grade | Implanted | Amount | Percentage | Weeks | CCA-PDX | Line ID |
| CCA Resection | well to moderate | 2 | 0 | \ | | \ | \ |
| | moderate | 3 | 1 | 33.3% | 7.0 | 1 | CCA-HS127 |
| | poor | 1 | 1 | 100.0% | 12.1 | 1 | CCA-HS131 |
| | total | 6 | 2 | 33.3% | 9.6 | 2 | |

| | | | | | Engraftment time | Passageable | Passageable |
|---------------|----------|-----------|--------|------------|------------------|-------------|-------------|
| Туре | Grade | Implanted | Amount | Percentage | Weeks | CCA-PDX | Line ID |
| CCA Biopsy | moderate | 2 | 1 | 50.0% | 19.1 | 1 | CCA-HB163 |
| | total | 2 | 1 | 50.0% | 19.1 | 1 | |